fluoxetine has been researched along with Seasonal Affective Disorders in 17 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors investigated the efficacy and safety of fluoxetine in the treatment of winter seasonal affective disorder." | 9.08 | Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. ( Corral, MR; Gorman, CP; Joffe, RT; Lam, RW; Levitt, AJ; Michalon, M; Morehouse, RL; Steiner, M; Tam, W; Watson, GD, 1995) |
| " This study investigated whether fluoxetine has antidepressant effects comparable to bright light in the treatment of seasonal affective disorder (winter type)." | 9.08 | Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder. ( Hawellek, B; Höflich, G; Kasper, S; Martinez, B; Möller, HJ; Nickelsen, T; Ruhrmann, S, 1998) |
| "The aim was to investigate the secretion profile of melatonin and seasonal affective disorder before and after treatment with fluoxetine." | 7.69 | Effect of fluoxetine on melatonin in patients with seasonal affective disorder and matched controls. ( Allen, NH; Childs, PA; Martin, NJ; Plaskett, L; Rodin, I; Smythe, PJ; Thompson, C, 1995) |
| "Fluoxetine was associated with greater treatment-emergent adverse events (agitation, sleep disturbance, palpitations), but both treatments were generally well-tolerated with no differences in overall number of adverse effects." | 6.72 | The Can-SAD study: a randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder. ( Enns, MW; Lam, RW; Levitan, RD; Levitt, AJ; Michalak, EE; Morehouse, R; Tam, EM, 2006) |
| "The authors investigated the efficacy and safety of fluoxetine in the treatment of winter seasonal affective disorder." | 5.08 | Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. ( Corral, MR; Gorman, CP; Joffe, RT; Lam, RW; Levitt, AJ; Michalon, M; Morehouse, RL; Steiner, M; Tam, W; Watson, GD, 1995) |
| " This study investigated whether fluoxetine has antidepressant effects comparable to bright light in the treatment of seasonal affective disorder (winter type)." | 5.08 | Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder. ( Hawellek, B; Höflich, G; Kasper, S; Martinez, B; Möller, HJ; Nickelsen, T; Ruhrmann, S, 1998) |
| "The aim was to investigate the secretion profile of melatonin and seasonal affective disorder before and after treatment with fluoxetine." | 3.69 | Effect of fluoxetine on melatonin in patients with seasonal affective disorder and matched controls. ( Allen, NH; Childs, PA; Martin, NJ; Plaskett, L; Rodin, I; Smythe, PJ; Thompson, C, 1995) |
| "Fluoxetine was associated with greater treatment-emergent adverse events (agitation, sleep disturbance, palpitations), but both treatments were generally well-tolerated with no differences in overall number of adverse effects." | 2.72 | The Can-SAD study: a randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder. ( Enns, MW; Lam, RW; Levitan, RD; Levitt, AJ; Michalak, EE; Morehouse, R; Tam, EM, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (23.53) | 18.2507 |
| 2000's | 9 (52.94) | 29.6817 |
| 2010's | 2 (11.76) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Mittal, M | 1 |
| Goel, RK | 1 |
| Bhargava, G | 1 |
| Mahajan, MP | 1 |
| Belge, JB | 1 |
| Sabbe, AC | 1 |
| Sabbe, BG | 1 |
| Nussbaumer-Streit, B | 1 |
| Thaler, K | 2 |
| Chapman, A | 2 |
| Probst, T | 1 |
| Winkler, D | 1 |
| Sönnichsen, A | 1 |
| Gaynes, BN | 2 |
| Gartlehner, G | 2 |
| Kawai, M | 1 |
| Goda, R | 1 |
| Otsuka, T | 1 |
| Iwamoto, A | 1 |
| Uotsu, N | 1 |
| Furuse, M | 1 |
| Yasuo, S | 1 |
| Delivuk, M | 1 |
| Kaminski, A | 1 |
| Swiecicki, Ł | 1 |
| Szafrański, T | 1 |
| Sakamoto, K | 1 |
| Murray, G | 3 |
| Michalak, EE | 5 |
| Levitt, AJ | 6 |
| Levitan, RD | 5 |
| Enns, MW | 5 |
| Morehouse, R | 5 |
| Lam, RW | 7 |
| Cox, BJ | 1 |
| Tam, EM | 3 |
| Cheung, A | 1 |
| Childs, PA | 1 |
| Rodin, I | 1 |
| Martin, NJ | 1 |
| Allen, NH | 1 |
| Plaskett, L | 1 |
| Smythe, PJ | 1 |
| Thompson, C | 1 |
| Gorman, CP | 1 |
| Michalon, M | 1 |
| Steiner, M | 1 |
| Corral, MR | 1 |
| Watson, GD | 1 |
| Morehouse, RL | 1 |
| Tam, W | 1 |
| Joffe, RT | 1 |
| Partonen, T | 1 |
| Lönnqvist, J | 1 |
| Ruhrmann, S | 1 |
| Kasper, S | 1 |
| Hawellek, B | 1 |
| Martinez, B | 1 |
| Höflich, G | 1 |
| Nickelsen, T | 1 |
| Möller, HJ | 1 |
| Lee, SK | 1 |
| Grewal, A | 1 |
| Yatham, LN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Placebo-Controlled Trial of Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder[NCT00502320] | Phase 4 | 50 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Clinician-rated measure of mood; evaluates classical 21 Hamilton Depression items, and 8-item subscale measuring atypical depression symptoms which commonly occur during SAD episodes. Score ranges from 0-89, higher scores indicate higher levels of depression. (NCT00502320)
Timeframe: Monthly for duration of treatment (up to 4 months)
| Intervention | scores on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Month 1 | Month 2 | Month 3 | Month 4 | |
| Placebo | 19.99 | 15.97 | 19.47 | 20.65 | 23.68 |
| Ramelteon | 22.68 | 16.16 | 14.81 | 11.69 | 9.15 |
Self-rated scale to measure severity of depressive symptoms. Score ranges from 25-100, higher scores reflect more depression. (NCT00502320)
Timeframe: Monthly for duration of treatment (up to 4 months)
| Intervention | scores on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Month 1 | Month 2 | Month 3 | Month 4 | |
| Placebo | 58.63 | 56.40 | 58.59 | 58.62 | 61.65 |
| Ramelteon | 63.06 | 54.35 | 53.51 | 49.26 | 46.14 |
Self-rated scale to measure quality of sleep via questions regarding sleep latency, duration, efficiency, disturbances, use of sleep medication, and daytime dysfunction. Score ranges from 0-21, higher scores represent more significant sleep disturbance. (NCT00502320)
Timeframe: Monthly for duration of treatment (up to 4 months)
| Intervention | scores on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Month 1 | Month 2 | Month 3 | Month 4 | |
| Placebo | 11.45 | 8.67 | 8.62 | 9.88 | 9.61 |
| Ramelteon | 11.56 | 9.52 | 7.57 | 8.07 | 7.05 |
3 reviews available for fluoxetine and Seasonal Affective Disorders
| Article | Year |
|---|---|
Second-generation antidepressants for treatment of seasonal affective disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Bias; Citalopram; Duloxetine Hydrochloride; Female; | 2021 |
Second-generation antidepressants for seasonal affective disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Duloxetine Hydrochloride; Female; Fluox | 2011 |
[Seasonal affective disorder].
Topics: Diagnostic and Statistical Manual of Mental Disorders; Female; Fluoxetine; Humans; Male; Moclobemide | 2003 |
9 trials available for fluoxetine and Seasonal Affective Disorders
| Article | Year |
|---|---|
Therapeutic mechanism in seasonal affective disorder: do fluoxetine and light operate through advancing circadian phase?
Topics: Adolescent; Adult; Aged; Circadian Rhythm; Fluoxetine; Humans; Light; Middle Aged; Seasonal Affectiv | 2005 |
O sweet spot where art thou? Light treatment of Seasonal Affective Disorder and the circadian time of sleep.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Circadian Rhythm; Combined Modali | 2006 |
Personality and seasonal affective disorder: results from the CAN-SAD study.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Diagnosis, Differential; Femal | 2006 |
The Can-SAD study: a randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder.
Topics: Adult; Canada; Combined Modality Therapy; Diagnostic and Statistical Manual of Mental Disorders; Dou | 2006 |
Quality of life as an outcome indicator in patients with seasonal affective disorder: results from the Can-SAD study.
Topics: Adult; Canada; Double-Blind Method; Female; Fluoxetine; Humans; Male; Phototherapy; Prospective Stud | 2007 |
Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder.
Topics: Adult; Ambulatory Care; Antidepressive Agents, Second-Generation; Female; Fluoxetine; Humans; Male; | 1995 |
Moclobemide and fluoxetine in treatment of seasonal affective disorder.
Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Benzamides; Dose-Respo | 1996 |
Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder.
Topics: Adult; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Phototherapy; Seasonal Af | 1998 |
An open trial of light therapy for women with seasonal affective disorder and comorbid bulimia nervosa.
Topics: Adolescent; Adult; Bulimia; Comorbidity; Female; Fluoxetine; Fluvoxamine; Humans; Multi-Institutiona | 2001 |
5 other studies available for fluoxetine and Seasonal Affective Disorders
| Article | Year |
|---|---|
PASS-assisted exploration of antidepressant activity of 1,3,4-trisubstituted-beta-lactam derivatives.
Topics: Animals; Antidepressive Agents; Chemistry, Pharmaceutical; Computational Biology; Crystallography, X | 2008 |
When is pharmacotherapy necessary for the treatment of seasonal affective disorder?
Topics: Fluoxetine; Humans; Phototherapy; Seasonal Affective Disorder | 2022 |
Antidepressant-like effect of bright light is potentiated by L-serine administration in a mouse model of seasonal affective disorder.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain; Disease Models, Animal; Fluoxetine; Light; | 2015 |
Side effects after phototherapy implementation in addition to fluoxetine or sertraline treatment: a report of two cases.
Topics: Adult; Drug Synergism; Female; Fluoxetine; Humans; Male; Middle Aged; Phototherapy; Seasonal Affecti | 2002 |
Effect of fluoxetine on melatonin in patients with seasonal affective disorder and matched controls.
Topics: Adult; Female; Fluoxetine; Humans; Hypothalamus; Male; Melatonin; Receptors, Adrenergic, beta-1; Sea | 1995 |